🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Artificial Intelligence for Diagnosing Diabetic Retinopathy in Primary Care

RecruitingNAAges 18 Years - anyAllHospital de Clinicas de Porto Alegre
NCT07236879 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a clinical trial to evaluate the effects of universal screening for diabetic retinopathy (DR) and diabetic macular edema (DME) using artificial intelligence (AI) in the interpretation of fundus photographs obtained by trained nursing assistant using a portable fundus camera in a primary care setting, compared with images obtained by the same method, but interpreted by ophthalmologists.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults (\> 18 years old) diagnosed with diabetes mellitus who agree to participate in the study. Exclusion Criteria: * Any contraindication for pharmacological mydriasis (such as knowledge of having closed-angle glaucoma, pregnancy). * Life expectancy less than 6 months
💊

What it tests

  • Mobile retinography interpreted by artificial intelligence
  • Mobile retinography interpreted by ophthalmologists
📍

Where

1 site
Hospital de Clínicas de Porto Alegre
Porto Alegre, Brazil
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy